MORF-440 for Healthy Subjects

Overseen ByThere may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or

Age: 18+

Sex: Any

Trial Phase: Phase 1

Sponsor: Morphic Holdings, Inc, a wholly owned subsidiary of Eli Lilly and Company

Disqualifiers: Pregnancy, Nicotine use, others

Trial Summary

What is the purpose of this trial?

The purpose of this study is to evaluate the safety and tolerability of single ascending doses of MORF-440 administered to healthy participants single-ascending dose (SAD) and maximum ascending dose (MAD) substudy.

Research Team

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)

Principal Investigator

Eli Lilly and Company

Eligibility Criteria

This trial is for healthy individuals who want to participate in a study testing the safety of a new medication called MORF-440. Specific eligibility criteria are not provided, but typically participants must meet certain health standards and cannot have conditions that would exclude them from safely participating.

Inclusion Criteria

Body mass index (BMI) within 18.0 kg/m² to 30.0 kg/m², inclusive

I am a male who either uses contraception or cannot father a child.

I am either not able to have children, use birth control, or have been menopausal for at least a year.

Exclusion Criteria

Nicotine intake (e.g., smoking, nicotine patch, nicotine chewing gum, chewing tobacco, electronic cigarettes) within 1 month before screening and/or inability to refrain from nicotine from screening until the end of the study

I am not pregnant, breastfeeding, or planning to become pregnant soon.

Timeline

Screening

Participants are screened for eligibility to participate in the trial

1-2 weeks

Treatment

Participants receive single ascending doses (SAD) and maximum ascending doses (MAD) of MORF-440

4 days

Daily visits for dosing and monitoring

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

Treatment Details

Interventions

MORF-440 (LY4292009)

Trial Overview The trial is examining the effects of single ascending doses of a drug named MORF-440 (LY4292009) compared to a placebo. It's designed to find out how safe the drug is and what tolerable dose range can be given without causing harm.

Participant Groups

11Treatment groups

Experimental Treatment

Placebo Group

Group I: Cohort B4 (Optional)Experimental Treatment1 Intervention